How to Prevent and Reverse Cognitive Decline: using personalised medicine to make Alzheimer’s a rare disease14 September 2019, Cavendish Conference Centre, London
Places are limited
Course gluten-free lunch
Registration opens at 9.30, with the conference finishing at 16.30. The full schedule will be confirmed shortly.
‘How to Prevent and Reverse Cognitive Decline’ Dale Bredesen
Alzheimer’s disease should be—and shall be—a rare disease. Just as former scourges leprosy, polio, and syphilis became rare diseases, so shall Alzheimer’s become a rare disease, but the therapeutic approach for Alzheimer’s will necessarily be quite different than it was for these infectious diseases. At the lectures, we shall discuss the first examples of the reversal of cognitive decline in Alzheimer’s disease and the personalized, precision medicine approach that has now been used in thousands of patients, as well as updates to this therapeutic approach.
About Dale Bredesen
Department of Molecular and Medical Pharmacology
David Geffen School of Medicine at UCLA, Los Angeles, CA
Founding President and Professor Emeritus, Buck Institute for Research on Aging, Novato, CA
Dr. Bredesen received his undergraduate degree from Caltech and his medical degree from Duke. He served as postdoctoral fellow in the laboratory of Nobel laureate Stanley Prusiner. He was the Founding President and CEO of the Buck Institute for Research on Aging, and Adjunct Professor at UCSF; then in 2013 he returned to UCLA as the Director of the Easton Center for Alzheimer’s Disease Research.
The Bredesen Laboratory studied basic mechanisms underlying the neurodegenerative process, and the translation of this knowledge into effective therapeutics for Alzheimer’s disease and other neurodegenerative conditions, leading to the publication of over 220 research papers. He established the Alzheimer’s Drug Development Network with Dr. Varghese John in 2008, leading to the identification of new classes of therapeutics for Alzheimer’s disease. He developed ReCODE, a new approach to the treatment of Alzheimer’s disease, leading to the first description of reversal of symptoms in patients with MCI and early Alzheimer’s disease, published in 2014, 2016, and 2018. His book, The End of Alzheimer’s, was a New York Times Bestseller, and was translated into 28 languages.
Book your place
Discounted early-bird Booking is now open until 1 February 2019. Places are limited and often sell out, so guarantee your place before it’s too late.
Book your place before it's too late...
Proudly supported by